All In Biotech

Investigational drug · Phase 2

Relmacabtagene Autoleucel

Also called: JWCAR029

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma.

Phase 2

Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

21

Any phase or sponsor naming "Relmacabtagene Autoleucel"

First trial start

2023

Nov 3, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Relmacabtagene Autoleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma Grade 3B
  • High-grade B-cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Relmacabtagene Autoleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 18 on PubMed

Also in development for Lymphoma, Large B-Cell, Diffuse

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • JNJ-90014496Phase 21 trial

    Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.